A practical reference on IGF-1: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-15 and is reviewed periodically as new material appears.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
== Dynamic structures and modifications == As in the broader field of DNA nanotechnology, DNA origami may be made dynamic in nature through the use of a variety of methods. The three primary methods of creating a dynamic DNA origami machine are toehold mediated strand displacement, enzymatic reactions, and base stacking. While these methods are most commonly used, additional methods for creating dynamic DNA origami machines exist, such as designing a directional component and using brownian motion to drive rotational movement of structures or leveraging less commonly used DNA self-assembly phenomena like G-quadruplexes or i-motifs which can be pH sensitive.
=== International agencies === The European Food Safety Authority (EFSA) warned that children who ate large amounts of confectionery and biscuits with high milk content could theoretically be consuming melamine at more than three times above prescribed EU safety limits (0.5 mg/kg of body weight). The EFSA said children with a mean consumption of products such as milk toffee, biscuits and chocolate containing contaminated powdered milk would not be at risk, and adults would not be at risk even in the worst-case scenarios. The World Health Organization, which was only notified on 11 September, asked Beijing why it took so many months for the scandal to become public, and to establish whether failure was deliberate or due to ignorance. WHO's representative in China, Hans Troedsson, said the issue of who knew what and when was critical, because knowledge would be the distinction between ignorance and neglect. WHO and UNICEF jointly decried the "deliberate contamination of foods intended for ... vulnerable infants and young children." Following a spate of mass national bans, the WHO urged national food safety authorities on 25 September to test Chinese dairy products for health risks before placing import bans or recalls. On 26 September, the WHO warned health officials to look out for tainted dairy products imported from China. International Food Safety Authorities (INFOSAN), a network organized by WHO and the Food and Agriculture Organization, suggested that countries should focus on smuggled formula.
== Epidemiology == Duchenne muscular dystrophy is the most common type of muscular dystrophy; it affects about one in 5,000 males at birth. Duchenne muscular dystrophy has an incidence of one in 3,600 male infants. In the US, a 2010 study showed a higher amount of those with Duchenne muscular dystrophy age ranging from 5 to 54 who are Hispanic compared to non-Hispanic Whites, and non-Hispanic Blacks.
Sources: en.wikipedia.org
Christine Coates, Director, Coates Engineering (International Ltd). For services to Economic Development in North West England. Paulene Mary Collins. For services to Legal Education. Charles John Cooper, Principal Professional and Technology Officer, Ministry of Defence. Derek MacDonald Cooper. For services to Radio Broadcasting. Commodore George Richard Cooper, , Chief of Operations, Royal National Lifeboat Institution. For services to the RNLI. David Leonard Court. For services to Tourism in East Anglia. The Honourable Jurat John Alexander Gore Coutanche, lately Jurat, Royal Court of Jersey. For services to the community. Squadron Leader Robert Frederick Craig, Royal Air Force (Retd.), lately Grade 7, Ministry of Defence. Adrian Robert Currie, , Chief Fire Officer, Devon Fire and Rescue Service. For services to the Fire Service. Professor John Darby. For services to Community Relations. William Roch Davies, lately Director, Welsh Centre for International Affairs. For humanitarian services. Sally Dawn Ridley-Day. For political and public service. Peter Denley. For services to the Rehabilitation of Offenders. Brian Charles Dice. For services to British Waterways. James Dick, Director of Social Work Services, The Highland Council. For services to Social Work. Elizabeth Ann Dodsworth. For political service. Margaret Duddy. For political and public service. Andrew Nicholas Duff. For political service. Sister Mary Vincent Duggan. For services to Education. Helen Simpson Dunsmore. For services to Higher Education. Albert John Edwards, .
=== Causality === Early case-control studies clearly showed a close association between smoking and lung cancer, but contemporary doctors and scientists did not feel evidence existed for causality. Follow-up large prospective cohort studies in the early 1950s showed clearly that smokers died faster, and were more likely to die of lung cancer, cardiovascular disease, and a list of other diseases which lengthened as the studies continued The British Doctors Study, a longitudinal study of some 40,000 doctors, began in 1951. By 1954 it had evidence from three years of doctors' deaths, based on which the government issued advice that smoking and lung cancer rates were related (the British Doctors Study last reported in 2001, by which time there were approximately 40 linked diseases). The British Doctors Study demonstrated that about half of the persistent cigarette smokers born in 1900–1909 were eventually killed by their addiction.
=== 11 May === The Ukrainian army said that they had broken through advancing Russian formations northwest of Bakhmut. Geolocated footage showed Ukrainian troops counterattacking near Khromove and Bila Hora, which Russian forces were trying to seize in order to encircle the city. Ukrainian sources said their forces advanced 2.6 km (1.6 mi) along a 3 km-wide (1.9-mile) front, destroying the 6th and 8th companies of the Russian 72nd Separate Motor Rifle Brigade; the head of the Wagner Group, Yevgeny Prigozhin, said already on 9 May that Russian troops had abandoned some positions on his flank in Bakhmut. The claim was also shared by Russian military bloggers but denied by the Russian Defence Ministry, which said that Russian forces repelled a surge of Ukrainian attacks in Soledar and that its forces had fallen back to "more favourable positions" near the Berkhivka reservoir northwest of Bakhmut for tactical reasons. The United Kingdom Secretary for Defence Ben Wallace announced that the UK supplied Ukraine with Storm Shadow missiles. With a range of 250 kilometres, the missiles are capable of hitting targets in Crimea from the positions currently held by Ukraine. The United States supported the UK's decision.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.